Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 9,983 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 9,983 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $1.14, for a total value of $11,380.62. Following the completion of the sale, the director owned 2,841,957 shares in the company, valued at approximately $3,239,830.98. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total value of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total transaction of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total transaction of $31,951.62.

Werewolf Therapeutics Stock Down 43.8%

Shares of HOWL traded down $0.47 during mid-day trading on Thursday, hitting $0.60. The company’s stock had a trading volume of 3,193,548 shares, compared to its average volume of 508,030. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The company’s 50-day moving average is $1.22 and its 200-day moving average is $1.32. Werewolf Therapeutics, Inc. has a 52-week low of $0.56 and a 52-week high of $2.38. The firm has a market capitalization of $29.17 million, a price-to-earnings ratio of -0.36 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HOWL. Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at about $48,000. Nuveen LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth about $71,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Werewolf Therapeutics in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HOWL. Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.